SAN DIEGO, March 23, 2016 /PRNewswire/ -- Mirati
Therapeutics, Inc. (NASDAQ: MRTX) today announced the promotion of
Jamie A. Donadio to Senior Vice
President and Chief Financial Officer, effective as of March 21, 2016.
Mr. Donadio first joined Mirati in 2013 serving as Vice
President of Finance. In his new role, he will be responsible for
all corporate finance and accounting activities for the
Company.
"We are pleased to expand Jamie's role," said Charles M. Baum, M.D., Ph.D., president and CEO
of Mirati. "Since joining the Company in 2013 Jamie has been
instrumental in building out our finance capabilities. As our
pipeline progresses and our business continues to grow, sound
financial planning and discipline will become even more important
as we work to advance our rich pipeline of targeted cancer
therapies. With over 15 years of experience in the
bio-pharmaceutical industry and a deep understanding of our
business we believe that Jamie is uniquely suited to lead our
finance team moving forward."
Prior to joining Mirati, Mr. Donadio spent 12 years at Amylin
Pharmaceuticals, Inc., most recently serving as Senior Director of
Finance, where he was responsible for corporate finance activities
including financial planning and analysis, treasury and capital
formation strategy. Mr. Donadio has an additional five years of
experience in corporate finance, having held previous roles at
Novatel Wireless and Ernst & Young.
About Mirati
Therapeutics
Mirati Therapeutics develops molecularly targeted, single agent and
immuno-oncology combination therapies intended to treat cancer.
Mirati's approach combines the three most important factors in
oncology drug development, 1) researching and developing drug
candidates that target genetic and epigenetic drivers of cancer, 2)
designing creative and agile clinical development strategies that
select for patients whose tumors are dependent on specific driver
alterations, and 3) leveraging a highly accomplished oncology
precision medicine leadership team. The Mirati team uses a
blueprint – proven by their prior work – for developing potential
breakthrough cancer therapies, with accelerated development paths,
in order to improve outcomes for patients. Mirati is advancing
three drug candidates through clinical development for multiple
oncology indications. More information is available at
www.mirati.com.
Logo - http://photos.prnewswire.com/prnh/20160307/341355LOGO
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/mirati-therapeutics-announces-promotion-of-jamie-a-donadio-to-chief-financial-officer-300239901.html
SOURCE Mirati Therapeutics, Inc.